Expert Opinion on Investigational Drugs
Overview
Expert Opinion on Investigational Drugs is a reputable peer-reviewed journal that provides insightful analysis and evaluation of the latest developments in the field of investigational drugs. With contributions from renowned experts, it offers comprehensive reviews, expert opinions, and critical assessments of emerging drugs, their potential therapeutic applications, and their impact on patient care. This journal serves as a valuable resource for researchers, clinicians, and pharmaceutical professionals seeking to stay updated on the most promising investigational drugs and their potential for
Details
Details
Abbr.
Expert Opin Investig Drugs
Start
1994
End
Continuing
Frequency
Monthly
p-ISSN
1354-3784
e-ISSN
1744-7658
Country
United Kingdom
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 2345
117
SJR / Ranks: 2164
1414
CiteScore / Ranks: 1464
9.90
JIF / Ranks: 1089
6.1
Recent Articles
1.
Bhatt A, Gupta P, Furie R, Vashistha H
Expert Opin Investig Drugs
. 2025 Mar;
:1-9.
PMID: 40047795
Introduction: Patients with Systemic Lupus Erythematosus (SLE) experience varied manifestations and unpredictable flares, complicating treatment and drug development. Despite these challenges, anifrolumab, voclosporin, and belimumab were approved by FDA. These...
2.
Madsbad S, Holst J
Expert Opin Investig Drugs
. 2025 Mar;
:1-19.
PMID: 40022548
Introduction: GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 ...
3.
Hoyek C, Zheng-Lin B, Jones J, Bekaii-Saab T
Expert Opin Investig Drugs
. 2025 Feb;
:1-8.
PMID: 40019490
Introduction: Over the past 20 years, the treatment landscape of HER2-amplified tumors has considerably evolved. Until now, no approved targeted therapies were available for patients with HER2-amplified metastatic colorectal cancer...
4.
Alkhouri N, Charlton M, Gray M, Noureddin M
Expert Opin Investig Drugs
. 2025 Feb;
PMID: 40016997
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated...
5.
Andrejic N, Bozovic I, Moradi H, Tataei R, Knezevic N
Expert Opin Investig Drugs
. 2025 Feb;
:1-13.
PMID: 40016085
Introduction: Neuropathic pain (NP) remains a significant challenge in clinical practice, requiring a sophisticated pharmacotherapeutic strategy for effective symptom management. This review provides a comprehensive analysis of the current pharmacological...
6.
Santoni M, Rizzo A, Massari F
Expert Opin Investig Drugs
. 2025 Feb;
:1-7.
PMID: 40012129
Introduction: Urothelial carcinoma (UC) is frequently associated with a poor prognosis in patients with advanced disease. A strong biological rationale supports the investigation of combining antibody-drug conjugates (ADCs) with immunotherapy...
7.
Mosalem O, Abdelhakeem A, Abdel-Razeq N, Babiker H
Expert Opin Investig Drugs
. 2025 Feb;
:1-12.
PMID: 40012027
Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited therapeutic options and poor overall survival. In recent years, advances in genomic profiling have revealed the complex molecular...
8.
Feigin A, Evans E, Fisher T, Zauderer M
Expert Opin Investig Drugs
. 2025 Feb;
:1-11.
PMID: 40007468
Introduction: Huntington's Disease (HD) is a progressive fatal neurodegenerative disease with an unmet need for disease-modifying therapies. Neuroinflammation, particularly astrogliosis, plays a crucial role in the pathogenesis of HD and...
9.
Irkec M, Konstas A, Hollo G, Dikmetas O, Algedik Tokyurek M, Bozkurt B
Expert Opin Investig Drugs
. 2025 Feb;
:1-13.
PMID: 40000961
Introduction: Glaucoma is a neurodegenerative disease that causes irreversible blindness worldwide. It results from retinal ganglion cell (RGC) loss and progressive optic nerve damage, mainly associated with elevated intraocular pressure...
10.
Susin-Calle S, Martinez-Rodriguez J, Munteis E, Villoslada P
Expert Opin Investig Drugs
. 2025 Feb;
:1-13.
PMID: 40000925
Introduction: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. While disease-modifying therapies have significantly improved the management of relapsing MS, progressive MS remains...